MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of marketable...
$51,556K
Proceeds from the
issuance of common stock...
$3,038K
Proceeds from the
exercise of stock options
$294K
Net cash provided by
investing activities
$8,101K
Net cash provided by
financing activities
$3,332K
Canceled cashflow
$43,455K
Net (decrease)
increase in cash, cash...
-$21,986K
Canceled cashflow
$11,433K
Stock-based compensation
expense
$2,488K
Non-cash lease expense
$1,269K
Depreciation
$932K
Prepaid expenses and
other current assets
-$471K
Accounts receivable
-$267K
Purchases of marketable
securities
$43,441K
Purchases of property and
equipment
$14K
Net cash used in
operating activities
-$33,419K
Canceled cashflow
$5,427K
Net loss
-$27,937K
Accrued expenses
-$5,126K
Accounts payable
-$2,290K
Operating lease
liabilities
-$1,933K
Deferred revenue
-$1,195K
Amortization of premiums and
discounts on marketable...
$365K
Back
Back
Cash Flow
source: myfinsight.com
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)